Allergan, Inc. (Allergan), a US-based medical device company, has reported total revenues of $1 billion for the first quarter of 2009, down compared with the total revenues of $1 billion in the year-ago quarter. It has also reported net earnings of $45 million, or $0.15 per diluted share, for the first quarter of 2009, compared with the net earnings of $107.9 million, or $0.35 per diluted share, in the year-ago quarter.

Allergan’s non-GAAP diluted earnings per share attributable to stockholders were $0.55 in the first quarter of 2009, compared to non-GAAP diluted earnings per share of $0.53 in the first quarter of 2008, a 3.8% year-over-year increase.

Product Sales

For the quarter ended March 31, 2009:

Allergan’s total product net sales were $994.6 million. Total product net sales decreased 6.3% as compared to total product net sales in the first quarter of 2008. On a constant currency basis, total product net sales decreased 0.4% compared to total product net sales in the first quarter of 2008.

Total specialty pharmaceuticals net sales decreased 3.6% as compared to total specialty pharmaceuticals net sales in the first quarter of 2008. On a constant currency basis, total specialty pharmaceuticals net sales increased 2.3% compared to total specialty pharmaceuticals net sales in the first quarter of 2008.

Total medical devices net sales decreased 17.6%, or 11.6% at constant currency, compared to total medical devices net sales in the first quarter of 2008.

“Our focused approach to the management of our costs as well as our businesses has once again allowed us to deliver solid financial results for the first quarter of 2009,” said David E.I. Pyott, chairman of the board and chief executive officer, Allergan “Furthermore, we are making excellent progress in our launch efforts for LATISSE (bimatoprost ophthalmic solution) 0.03% and are very pleased with the positive feedback we have received thus far from the market.”

Product and Pipeline Update

During the first quarter of 2009:

GlaxoSmithKline received approval of BOTOX (botulinum toxin type A) for the treatment of glabellar lines and equinus foot due to lower limb spasticity in juvenile cerebral palsy patients in Japan. GlaxoSmithKline also received approval of BOTOX for the treatment of glabellar lines in China.

Allergan’s New Drug Application seeking approval of POSURDEX for macular edema associated with retinal vein occlusion was granted priority review status by the U.S. Food and Drug Administration (FDA).

Following the end of the first quarter of 2009:

Allergan received approval of LUMIGAN (bimatoprost ophthalmic solution) 0.01% for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension in Canada.

Allergan commented on FDA requested class labeling for botulinum toxin treatments.

Outlook

For the full year of 2009:

All guidance provided on February 4, 2009 remains unchanged.

For the second quarter of 2009, Allergan estimates:

Total product net sales between $1,050 million and $1,100 million.

Non-GAAP diluted earnings per share attributable to stockholders guidance between $0.66 and $0.68.